The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImmupharma Share News (IMM)

Share Price Information for Immupharma (IMM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 2.075
Bid: 2.05
Ask: 2.09
Change: 0.00 (0.00%)
Spread: 0.04 (1.951%)
Open: 2.075
High: 0.00
Low: 0.00
Prev. Close: 2.075
IMM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: ImmuPharma hits milestone; Shearwater contract

Wed, 13th Apr 2022 11:06

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.

----------

AIM - WINNERS

----------

ImmuPharma PLC, up 59% at 9.00 pence, 12-month range 4.80p-10.90p. "Delighted" with positive data from the Lupuzor/P140 pharmacokinetic study, required by the US Food & Drug Administration, as part of the new optimised international Phase 3 trial of Lupuzor in lupus patients. Study shows PK study has met the key endpoints requested by the FDA. "This positive PK data now clears the path for commencement of all clinical studies within the P140 platform. In addition to lupus, there is a planned Phase 2a/3 pivotal trial in chronic inflammatory demyelinating polyneuropathy," company notes.

----------

Shearwater Group PLC, up 25% at 136.42 pence, 12-month range 70.00p-230.00p. Subsidiary Brookcourt Solutions wins "significant" new contract win to the potential value of up to about GBP21.0 million with unnamed "leading telecommunications and media company". Initial, secured value of the contract, across an initial three year term, is GBP12.9 million, with the contract including an option to extend by a further two years for a total additional value of about GBP8.0 million.

----------

AIM - LOSERS

----------

Amur Minerals Corp, down 13% at 1.50 pence, 12-month range 1.00p-3.90p. Notes no individual or entity tied to company's AO Kun-Manie mine have been sanctioned in any round of EU, UK and US sanctions against Russia. Mine is in far east of Russia. Also notes flow of funds supporting AO Kun-Manie continue and company has now ensured sufficient cash reserves for the subsidiary covering budgeted costs through the first half 2022. Previously, AO Kun-Manie funds have been delivered to cover a 30 to 45 day period. Does say, however, company's lead legal consul representation in Moscow, Bryan Cave Leighton Paisner, is suspending operations within Russia. Company is reviewing options for lead Russian legal representation.

----------

By Paul McGowan; paulmcgowan@alliancenews.com

Copyright 2022 Alliance News Limited. All Rights Reserved.

More News
20 Dec 2021 11:41

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

AIM WINNERS & LOSERS: Fundraise lifts ImmuPharma; Proteome wins deal

Read more
20 Dec 2021 11:22

ImmuPharma raises £3.55m to fund research pipeline

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced subscriptions and a placing to raise £3.55m on Monday, to fund its research and development pipeline as well as general working capital.

Read more
20 Dec 2021 10:15

ImmuPharma surges after raise at "significant premium" to share price

ImmuPharma surges after raise at "significant premium" to share price

Read more
29 Nov 2021 20:45

TRADING UPDATES: ImmuPharma teams with Imperial; Webis results delayed

TRADING UPDATES: ImmuPharma teams with Imperial; Webis results delayed

Read more
29 Nov 2021 13:32

ImmuPharma signs two-year collaboration deal with Imperial College

(Sharecast News) - Specialist drug discovery and development company ImmuPharma announced on Monday that it has signed a two-year collaboration agreement with Imperial College London.

Read more
18 Nov 2021 20:53

TRADING UPDATES: Abingdon Health swings to loss; MetalNRG in dispute

TRADING UPDATES: Abingdon Health swings to loss; MetalNRG in dispute

Read more
18 Nov 2021 15:16

ImmuPharma reports 'significant' progress since restructure

(Sharecast News) - Specialist drug discovery and development company ImmuPharma reported "significant" positive progress on Thursday, following major changes to its board and a restructuring of senior management in August.

Read more
1 Oct 2021 11:47

IN BRIEF: Immupharma leaves Euronext Growth Brussels market

IN BRIEF: Immupharma leaves Euronext Growth Brussels market

Read more
29 Sep 2021 20:31

IN BRIEF: ImmuPharma to make cost savings as it simplifies structure

IN BRIEF: ImmuPharma to make cost savings as it simplifies structure

Read more
29 Sep 2021 13:22

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

EARNINGS UPDATES: Pittards swings to profit; Immupharma loss widens

Read more
24 Aug 2021 15:08

DIRECTOR DEALINGS: Gamesys, Capital and ActiveOps execs sell shares

DIRECTOR DEALINGS: Gamesys, Capital and ActiveOps execs sell shares

Read more
12 Aug 2021 14:17

IN BRIEF: Immupharma gets US FDA approval for Lupuzor pre-trial study

IN BRIEF: Immupharma gets US FDA approval for Lupuzor pre-trial study

Read more
12 Aug 2021 13:02

FDA gives ImmuPharma go-ahead for pharmacokinetic study

(Sharecast News) - Specialist drug discovery and development company ImmuPharma said on Thursday that the United States Food and Drug Administration (FDA) has approved the start of the pharmacokinetic study as part of its new, "optimised" international phase 3 trial of 'Lupuzor'.

Read more
30 Jul 2021 15:34

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

EXECUTIVE CHANGES: All change for ImmuPharma board as CEO departs

Read more
16 Jul 2021 11:24

IN BRIEF: ImmuPharma appoints COO Tim Franklin to board of directors

IN BRIEF: ImmuPharma appoints COO Tim Franklin to board of directors

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.